Publications by authors named "Imai Michitaka"

Claim this Profile
S
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Michitaka Imai

Hepatol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Michitaka Imai

J Gastroenterol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease.
Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Michitaka Imai

Hepatol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab.
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Michitaka Imai

Liver Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Michitaka Imai

Hepatol Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis.
Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Michitaka Imai

Hepatol Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Michitaka Imai

Liver Int· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma.
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Michitaka Imai

Oncology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.
Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Michitaka Imai

Liver Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma.
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Michitaka Imai

Liver Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Mara Persano, Andrea Casadei-Gardini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Michitaka Imai

Oncology· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study.
Atsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, Michitaka Imai

Hepatol Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Michitaka Imai

J Gastroenterol Hepatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Michitaka Imai

J Gastroenterol Hepatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.
Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Michitaka Imai

Hepatol Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient.
Atsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, Takeshi Hatanaka, Satoru Kakizaki, Michitaka Imai

Oncology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Michitaka Imai

Sci Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.
Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Takeshi Hatanaka, Michitaka Imai

Cancer Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Michitaka Imai

Aliment Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Michitaka Imai

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular Carcinoma.
Yuichi Hirano, Kazuhiro Nouso, Kazuya Kariyama, Atsushi Hiraoka, Shohei Shiota, Michitaka Imai

Acta Med Okayama· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic guide for immune checkpoint inhibitor-induced liver injury.
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru

Hepatol Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Michitaka Imai

Target Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Michitaka Imai

Aliment Pharmacol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, Shigeo Shimose, Goki Suda, Michitaka Imai

Liver Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis